Skip to Content
MilliporeSigma
All Photos(1)

Documents

T4580

Sigma-Aldrich

Tiludronate disodium salt hydrate

≥98% (HPLC)

Synonym(s):

Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H7ClNa2O6P2S · xH2O
CAS Number:
89987-06-4
Molecular Weight:
362.57 (anhydrous basis)
MDL number:
MFCD16872037
UNSPSC Code:
12352200
PubChem Substance ID:
329826798
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

H2O: >10 mg/mL, clear

originator

Sanofi Aventis

SMILES string

O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O

InChI

1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2

InChI key

SZVJRJRMQCKFON-UHFFFAOYSA-L

Biochem/physiol Actions

Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anne Sutcliffe
Nursing times, 105(7), 14-15 (2009-03-31)
This is the second of a two-part unit on Paget's disease. Part 1 outlined the epidemiology, pathophysiology, causes and clinical features of the condition. This part outlines advice on diagnosis, drug therapy, surgery, other management options and emotional support.
Deepali D Deshmukh et al.
Drug delivery, 17(3), 145-151 (2010-02-09)
The efficacy of n-lauryl-beta-D-maltopyranoside, (dodecylmaltoside, DDM) as a permeability-enhancer for tiludronate and cromolyn (BCS Class III, water-soluble compounds with oral bioavailability < 5%) was evaluated in Caco-2 cell monolayers and rat intestinal sacs. In Caco-2 cells samples were collected over
Fred Joshua et al.
Arthritis and rheumatism, 48(8), 2321-2323 (2003-08-09)
To determine whether resistance to one bisphosphonate predicts resistance to another bisphosphonate. One hundred patients with Paget's disease were treated with intravenous (IV) pamidronate. The initial dose was 120 mg, followed by further doses of 240 mg, until either biochemical
Nabil Saba et al.
Oncology, 68(1), 10-17 (2005-03-19)
With recent advances in cancer management, patients with metastatic bone disease are likely to have a prolonged clinical course, with skeletal-related events such as pain, hypercalcemia, pathologic fractures, spinal cord and nerve compression. Bisphosphonate use has resulted in the reduction
Stuart L Silverman
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 14(5), 299-305 (2008-10-08)
Paget disease of bone is a disorder of unknown etiology involving disturbances in bone remodeling, typically leading to bone pain and other complications such as skeletal deformities, fractures, hearing loss, and neurologic complications. Bisphosphonates (BPs), both oral and intravenous, have
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service